ISDA

Entry Detail

PDB ID:

6PRF

Keywords:

Hydrolase/Hydrolase Inhibitor

Title:

HIV-1 Protease multiple drug resistant clinical isolate mutant PR20 with GRL-14213A

Biological Source:

Source Organism:

Human immunodeficiency virus type 1 group M subtype

Host Organism:

Escherichia coli BL21

PDB Version:

Deposition Date:

2019-07-10

Release Date:

2019-09-18

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.21 Å

R-Value Free:

0.18

R-Value Work:

0.15

R-Value Observed:

0.15

Space Group:

P 61

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Protease
Mutations:Q7K, L10F, I13V, I15V, D30N, V32I, L33F, E35D, M36I, S37N, I47V, I54L, Q58E, I62V, L63P, C67A, A71V, I84V, N88D, L89T, L90M, C95A
Chain IDs:A, B
Chain Length:99
Number of Molecules:2
Biological Source:Human immunodeficiency virus type 1 group M subtype

UniProt ID:P03366 Pfam ID:PF00077 EC:3.1.26.13

Ligand Molecules

7OA

Primary Citation

Potent antiviral HIV-1 protease inhibitor combats highly drug resistant mutant PR20.

Kneller, D.W, Agniswamy, J, Ghosh, A.K, Weber, I.T.Show

Biochem.Biophys.Res.Commun. 519 61 66 (2019)

PMID: 31474336 DOI: 10.1016/j.bbrc.2019.08.126

Abstact

Drug-resistance threatens effective treatment of HIV/AIDS. Clinical inhibitors, including darunavir (1), are ineffective for highly resistant protease mutant PR20, however, antiviral compound 2 derived from 1 with fused tricyclic group at P2, extended amino-benzothiazole P2' ligand and two fluorine atoms on P1 shows 16-fold better inhibition of PR20 enzyme activity. Crystal structures of PR20 and wild-type PR complexes reveal how the extra groups of 2 counteract the expanded ligand-binding pocket, dynamic flaps, and faster dimer dissociation of PR20.

Legend

Protein

Chemical

Disease

Primary Citation of related structures